2 withdrawn. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Withdrawn 2 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Acute Lymphoblastic Leukemia: new trials by email Literature Review of Acute Lymphoblastic Leukemia trials Research Report on Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia Tisagenlecleucel, Blinatumomab, Inotuzumab - Acute Lymphoblastic Leukemia | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2020-06-05 | 2020-07-09 | |
| Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL Dasatinib - Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Withdrawn | Bristol-Myers Squibb | 2006-12-01 | 2016-02-17 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Bronchiolitis Obliterans Syndrome (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia (2) · Leukemia, Lymphoid (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Bone Marrow Diseases (1) · Bronchial Diseases (1) · Bronchiolitis (1) · Bronchiolitis Obliterans (1) · Bronchitis (1)
Dasatinib (1) · Inotuzumab Ozogamicin (1) · blinatumomab (1) · tisagenlecleucel (1)
Bristol-Myers Squibb (1) · Novartis Pharmaceuticals (1)
Hungary (1) · Italy (1) · Netherlands (1) · Poland (1) · Russia (1) · United Kingdom (1)